50 results on '"Prabhu, Vimalanand S."'
Search Results
2. Correction: Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe
3. Burden of CIN2+ diagnoses and conizations in women aged 18–45 years—a retrospective secondary data analysis of German statutory health insurance claims data
4. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice
5. Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe
6. Abstract B017: Disease free survival as a predictor of overall survival in patients with high-risk endometrial cancer receiving adjuvant chemotherapy
7. Relative importance of individual insurance status and hospital payer mix on survival for women with cervical cancer
8. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States
9. Adjuvant and first line chemotherapy use for endometrial cancer
10. Information needs during cancer care: qualitative research with advanced cervical cancer patients in Brazil, China, Germany, and the United States
11. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
12. The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
13. HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States
14. Real-world utilization of lenvatinib and pembrolizumab combination therapy for the treatment of endometrial cancer in the USA
15. #894 Real-world treatment patterns in recurrent or advanced endometrial cancer patients who initiated second-line systemic therapy in 5 European countries: a retrospective chart review study
16. #888 Real-world treatment patterns in recurrent or advanced endometrial cancer patients who initiated first-line systemic therapy in 5 European countries: a retrospective chart review study
17. Real-world utilization of lenvatinib and pembrolizumab combination therapy for the treatment of endometrial cancer in the USA.
18. Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States
19. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection
20. Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
21. Corrigendum to “Adjuvant and first line chemotherapy use for endometrial cancer” [Gynecol. Oncol. Rep. 41 (2022) 101002]
22. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States
23. 2022-RA-712-ESGO Real-world prevalence of microsatellite instability testing and related status in patients with recurrent or advanced endometrial cancer initiating first line of therapy in Europe
24. 2022-RA-702-ESGO Real-world treatment patterns and outcomes in recurrent or advanced endometrial cancer patients initiating 1st-line systemic therapy in Europe: a retrospective chart review study
25. Abstract 6276: Real-world prevalence of MSI/MMR testing for patients with recurrent or advanced endometrial cancer in Europe
26. Treatment patterns and outcomes among patients with recurrent or advanced endometrial cancer in Europe: Endometrial Cancer Health Outcomes Europe (ECHO EU) Study.
27. Healthcare Costs and Resource Use Associated With Cervical Intraepithelial Neoplasia and Cervical Conization: A Retrospective Study of German Statutory Health Insurance Claims Data
28. Estimating the Burden of 2009 Pandemic Influenza A (H1N1) in the United States (April 2009-April 2010)
29. Tests of Intrahousehold Resource Allocation Using a CV Framework: A Comparison of Husbands’ and Wives’ Separate and Joint WTP in the Slums of Navi-Mumbai, India
30. Corrigendum: Economic Value of Lost Productivity Attributable to Human Papillomavirus Cancer Mortality in the United States
31. Additional file 1 of HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States
32. Additional file 1 of The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
33. Treatment patterns and outcomes among patients with microsatellite stable (MSS) advanced endometrial cancer in the United States: Endometrial Cancer Health Outcomes (ECHO) retrospective chart review Study.
34. Drivers and barriers to information seeking: Qualitative research with advanced cervical cancer patients in the United States.
35. Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician’s choice (TPC).
36. Median Age at HPV Infection Among Women in the United States: A Model-Based Analysis Informed by Real-world Data
37. Economic Value of Lost Productivity Attributable to Human Papillomavirus Cancer Mortality in the United States
38. Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States
39. Sexually acquired HIV infections in the United States due to acute-phase HIV transmission: an update
40. Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials
41. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection
42. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States
43. Cost-effectiveness of pooled nucleic acid amplification testing for acute HIV infection after third-generation HIV antibody screening and rapid testing in the United States: a comparison of three public health settings
44. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections
45. Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach
46. Cost-effectiveness of ceftolozane/ tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States
47. Cost-Effectiveness of HIV Screening in STD Clinics, Emergency Departments, and Inpatient Units: A Model-Based Analysis
48. Cost-Effectiveness of Newborn Circumcision in Reducing Lifetime HIV Risk among U.S. Males
49. Real-world first-line treatment patterns and outcomes in recurrent/advanced endometrial cancer patients in Europe.
50. Corrigendum to "Adjuvant and first line chemotherapy use for endometrial cancer" [Gynecol. Oncol. Rep. 41 (2022) 101002].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.